Show All
What does LumiraDx do?

We are a next-generation point of care diagnostic company addressing the current limitations of legacy systems by bringing lab-comparable performance to the point of care in minutes, on a single Instrument with a low cost of ownership. We are focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need, thereby enabling more informed medical decisions to improve health outcomes while lowering costs.

We have developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity. With our Platform, our goal is to address the key challenges faced by healthcare providers in providing efficient and cost-effective patient care in a community setting.

When was LumiraDx founded?
LumiraDx was founded in 2014 by a group of entrepreneurs: Ron Zwanziger, our Chairman and Chief Executive Officer; Dave Scott, Ph.D., our Chief Technology Officer; and Jerry McAleer, Ph.D., our Chief Scientist.
Where is the company headquarters?
LumiraDx is headquartered at 3 More London Riverside, London, SE1 2AQ, United Kingdom.
When did LumiraDx become a public company?
LumiraDx became a public company on 29th September 2021, in connection with its merger with CA Healthcare Acquisition Corp. The surviving company is LumiraDx Limited (Nasdaq: LMDX).
What is LumiraDx’s CUSIP number?
The CUSIP number for LumiraDx’s common shares is G5709L 109. The CUSIP number for LumiraDx’s warrants exercisable for common shares is G5709L 117.
How are LumiraDx’s shares and warrants traded?
LumiraDx’s common shares are traded on the Nasdaq Global Market under the ticker symbol “LMDX” and LumiraDx’s warrants exercisable for common shares are traded on the Nasdaq Global Market under the ticker symbol “LMDXW.”
How may I view documents LumiraDx has filed with the Securities & Exchange Commission (SEC)?
LumiraDx’s SEC filings may be viewed on our Investor Relations page under Financial Information or at
Who are LumiraDx’s Stock Transfer Agent?
Telephone inquiries: 1-888-888-8888, option 1 (U.S.)
1-888-888-8888, option 1 (non U.S.)
E-mail inquiries:

Written requests:
By Mail:
P.O. Box 505000
Louisville KY 40233-5000

By Overnight Delivery:
462 South 4th Street, Suite 1600
Louisville KY 40202
Who is LumiraDx’s independent auditor?
LumiraDx’s independent auditor is KPMG LLP.
Who are LumiraDx’s Executive Management team and Board of Directors?
This information can be found on the “Who We Are” section of our website.
Does LumiraDx have operations outside of the United States?
Yes. LumiraDx is headquartered in the UK with R&D and manufacturing centers in Scotland, England and the U.S., and sales and marketing operations across Western Europe, the U.S., Japan, South Africa, Colombia, and Brazil.
Who should I contact regarding investor inquiries?
Please contact
Where can I get more information about LumiraDx?
For more information about LumiraDx, please visit our website at